Please enlighten us:
Details of your calculations forming a basis for your conclusion..
If the technology does not gain CE and or TGA approvals then your assumption may be correct however it is highly unlikely given the outstanding results from our Australian clinical study and having been granted ISO clearance tack on the partial outstanding results from the US paediatric clinical study which in turn will see FDA clearance over the coming months too. At 5 to $10 per use with over 700 million respiratory visits to the doctor annually and with initial uptake from an ever-expanding telehealth community I beg to differ..
Throw in sleep apnea and any other new verticals that the company has stated are working on... LOL show me some evidence until then I see your post as a down ramp and a big fat joke!
Look forward to your next post with some substance please..
Cheers
Red bar
- Forums
- ASX - By Stock
- RAP
- Title moderated
Title moderated
-
- There are more pages in this discussion • 18 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
Featured News
Add RAP (ASX) to my watchlist
(20min delay)
|
|||||
Last
20.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $176.2M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
RAP (ASX) Chart |
Day chart unavailable
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online